乌苯美司对肺鳞癌化疗患者免疫功能的影响  

Effects of ubenimex (bestatin) on the immunity of patients with squamous cell lung carcinoma treated with chemotherapy

作　　者：李平[1] 徐泳[1] 任莉[1] 杨玉琼[1] 张洪[1] 罗德云[1] 郝德治[1] 洪元康[1] 陈礼金 谢名英[1] 

机构地区：[1]四川大学华西医院(原华西医科大学附属第一医院)肿瘤中心,成都610041

出　　处：《中国肺癌杂志》2001年第5期364-366,共3页Chinese Journal of Lung Cancer

摘　　要：目的　评价乌苯美司对肺鳞癌化疗患者免疫功能的影响。方法　将 5 6例未手术肺鳞癌患者按3∶2的比例随机分入试验组 ( 34例 )及对照组 ( 2 2例 ) ,患者均接受CAP方案化疗 ,每 2 1天为 1周期 ,共 3个周期 ;试验组加服乌苯美司 30mg ,每日 1次 ,共 6个月。分析化疗疗效 ,观察治疗前、治疗后 3、6个月淋巴细胞绝对计数 (LC)、OKT4/T8、NK细胞活性、血清IL 2、SIL 2R水平的变化情况。结果　在可评价的 5 2例 (试验组32例 ,对照组 2 0例 )患者中 ,两组间近期化疗疗效无统计学差异 (P >0 .0 5 )。治疗后 3、6个月 ,试验组OKT4/T8比值、NK细胞活性及IL 2水平均较治疗前明显提高 (P <0 .0 5 ) ,但前二项指标与对照组比较无统计学差异(P >0 .0 5 ) ,而后一项则有明显统计学差异 (P <0 .0 5 ) ;治疗后 3、6个月 ,试验组患者血清SIL 2R水平均较治疗前降低 (P <0 .0 5 ) ,但组间比较无统计学意义 ,而对照组除治疗后 6月SIL 2R水平较治疗前明显降低外 (P<0 .0 5 ) ,其余各项指标与治疗前比较均无显著性差异。结论　乌苯美司对肺鳞癌化疗患者OKT4/T8比值、NK细胞活性、血清IL 2和SIL 2R有一定程度的改善作用 ,但其临床应用价值仍需进一步观察确定。Objective To evaluated the effects of ubenimex on immunity of patients with squamous cell lung cancer. Methods Fifty six patients with inoperable squamous cell lung carcinoma were randomly divided into the experimental group (EG, received chemotherapy combined with ubenimex 30?mg p.o. daily for 6 months) or the control group (CG, received chemotherapy alone) at 3∶2 ratio. Lymph ocyte counting (LC), OKT 4/T 8 ratio, activity of NK cell, IL 2 value and the level of soluble interleukin 2 receptor were determined. The regimen was CAP: cyclophosphamide and adriamycin and cisplatin. Results Fifty two patients were evaluable to be analysed and 32 in the EG and 20 in the CG respectively. The overall response rate at 6 months after treatment was 56% (18/32) in the EG and 45% (9/20) in the CG, which was no significant difference between the two groups. Three months and 6 months after treatment, OKT 4/T 8 ratio, activity of NK cell and IL 2 value of the patients in the EG were significantly increased with the values of 1.50±0.29 and 1.63±0.39, 35.1%±7.3% and 35.8%±5.0%, 12±2?IU/ml and 13±3?IU/ml respectively compared with those before treatment with the values of 1.34±0.32, 33.6%±5.5%, 11±2?IU/ml respectively (P<0.05) and the SIL 2R level was significantly decreased with the values of 596±140?IU/ml and 581±138?IU/ml respectively compared with those before treatment 660±173?IU/ml (P<0.05). Whereas in the CG there were no significant changes observed except for the SIL 2R level with the value of 532±78?IU/ml at 6 months after treatment vs 645±189?IU/ml before treatment. The IL 2 level of the patients in the EG significantly increased compared with those in the CG (P<0.05) at 6 months after treatment (13± 3?IU/ml vs 11±3?IU/ml). Conclusion Ubenimex may increase the OKT 4/T 8 ratio, the NK cell activity and the IL 2 value and decrease the SIL 2R level of patients with squamous cell lung carcinoma. Further studies on larger cases and long period of follow up will be needed before definit

关 键 词：乌苯美司 非小细胞肺癌 免疫疗法 化疗 白细胞介素-2 肺鳞癌 

分 类 号：R734.2[医药卫生—肿瘤] R979.1[医药卫生—临床医学]